Aptus Pharma Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Aptus Pharma Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹70
Per ShareLot Size
2000 Shares
Minimum Investment
₹1,40,000
Issue Size
₹13.02 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35.11%
QIB Quota
49.83%
NII Quota
15.06%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Aptus Pharma Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
100%
Promoter Holding (Post-Issue)
72.89%
Issue Type
Book Building - SME
ISIN
INE15XJ01010
About the Company
Our Company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. While the Company does not own any manufacturing facilities, it operates through a contract manufacturing model. We do not own any manufacturing plants but has entered into contract manufacturing agreement with seven manufacturing units. under various arrangements. Of these, we have formal loan and license agreements in place with two manufacturing units. The remaining production is carried out through informal arrangements with Other Manufacturers, based on purchase orders (PO). We provide a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.
Industry Overview
As there has been a growing consensus over providing new innovative therapies to patients, Indian pharmaceutical market is estimated to touch US$ 130 billion in value by the end of 2030 and US$ 450 billion market by 2047. India ranks 3rd worldwide for pharmaceutical production by volume and 14th by value. The country has an established domestic pharmaceutical industry, with a strong network of 3,000 drug companies and ~10,500 manufacturing units. India's drugs and pharmaceuticals exports stood at US$ 27.82 billion in FY24 (April- March) and stands at US$ 14.42 billion in FY25 (April-September). According to Government data, the Indian pharmaceutical industry is worth approximately US$ 50 billion with over US$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India. During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6- 8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market. The Indian pharmaceutical industry has seen a massive expansion over the last few years and is expected to reach about 13% of the size of the global pharma market while enhancing its quality, affordability, and innovation. Indian pharmaceutical sector is expected to grow at a CAGR of 22.4% in the near future. The government has set ambitious target to boost the medical devices industry in India, aiming to elevate it from its current US$ 11 billion valuation to US$ 50 billion by 2030. India is the second-largest contributor of global biotech and pharmaceutical workforce. Exports of drugs and pharmaceuticals recorded a strong y-o-y growth of 9.7% during April-March FY24. The Indian healthcare industry reached over US$ 370 billion in 2022 and is expected to reach over US$ 610 billion by 2026. Indian hospital market valued at US$ 98.98 billion in FY23 and projected to grow by 8% CAGR and reached to US$193.59 billion by FY32. India is among the top 12 destinations for biotechnology worldwide and third largest in Asia Pacific. The country holds 3-5% of the global biotechnology industry pie. In 2022, India's bioeconomy was valued at US$ 137 billion, and aims to achieve US$ 300 billion mark by 2030.
Company History
Our Company was originally incorporated as "Aptus Pharma Private Limited", as a private limited company under the Companies Act, 1956, with the Registrar of Companies ("ROC"), Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010. Subsequently, our Company was converted into a public limited company pursuant to a resolution passed by our Shareholders at an extraordinary general meeting held on November 30, 2024 and consequently the name of our Company was changed to "Aptus Pharma Limited" and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre.
Products & Services
- The Company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations.
Growth Strategy
- Hybrid Model for Growth.
- Dynamic Marketing Approach.
- Strategic Product Selection.
- Two-Sword Theory.
- Collaboration and Operational Efficiency.
- Human Resources Excellence.
- Enhancement of geographical presence.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public issue of up to 18,60,000 equity shares of face value of Rs. 10/- each ("Equity Shares") of Aptus Pharma Limited (the "Company" or "Aptus" or "Issuer") at an issue price of Rs. 70 per equity share (Including a share premium of Rs.60 per equity share) for cash, aggregating up to Rs. 13.02 crores ("Public Issue") out of which 94,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 70 per equity share for cash, aggregating Rs.0.66 crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. issue of 17,66,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 70 per equity share for cash, aggregating up to Rs.12.36 crores is hereinafter referred to as the "Net Issue". The public issue and net issue will constitute 27.11 % and 25.74 % respectively of the post-issue paid-up equity share capital of the company. Price Band: Rs. 70/- for equity share of face value of Rs. 10 each. The floor price is 14.00 times times the face value of the face value of the equity shares. Bids can made for a minimum of 4,000 equity shares and in multiples of 2,000 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Diversified Product Portfolio.
- Robust and Responsive Distribution Network.
- Strategic Manufacturing Partnerships.
- Commitment to High-Quality Standards.
- Competitive and Cost-Effective Pricing.
- The company does not have its own manufacturing facility for pharmaceutical products and the company have to relies on third parties for contract manufacturing of the products sold by the Company.
- The company is required to obtain, renew or maintain certain material statutory and regulatory permits and approvals required to operate its business, and if the company fail to does so in a timely manner or at all, its may be unable to operate the company business and its results of operations may be adversely affected.
- The company derives a significant part of the company revenue from few customers. If one or more of such customers choose not to source their requirements from the company or to terminate its contracts or purchase orders, the company business, cash flows, financial condition and results of operations may be adversely affected.
- If the company are unable to protect its intellectual property rights, the company business, results of operations and financial condition may be adversely affected. Further, if its products were found to be infringing on the intellectual property rights of a third-party, the company could be required to cease selling the infringing products, causing the company to lose future sales revenue from such products and face substantial liabilities for infringement of intellectual property rights.
- The Company may be exposed to product liability and other claims arising from defective medicines manufactured by third-party Contract Manufacturers, despite having manufacturing agreements in place, as indemnity terms are not pre-determined.